News
-
07.11.2023Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria’s Novel Biologic to Treat Pulmonary SarcoidosisPress ReleasesPerkins Coie is pleased to have advised Xentria Inc. in its exclusive multi-year licensing agreement with Meitheal Pharmaceuticals, Inc. to commercialize its novel biologic XTMAB-16 for pulmonary sarcoidosis in North America.
-
05.15.2018Perkins Coie Announces Life Sciences Blog: 1600 PTAB & BeyondPress ReleasesPerkins Coie is proud to announce the launch of 1600 PTAB & Beyond, a blog that reports from the intersection of the life sciences industry and key decisions and developments from the Patent Trial and Appeal Board (PTAB), district courts and appellate courts.